Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251705 | 0.83 | CCNA2 (0.33) | CCNA2CDK2GRM1ALDH1A1KDM4E | |
| SCHEMBL20680456 | 0.82 | CCNA2 (0.34) | CCNA2CDK2GRM1ALDH1A1 | |
| SCHEMBL29598023 | 0.82 | CCNA2 (0.34) | CCNA2CDK2GRM1ALDH1A1 | |
| SCHEMBL24496622 | 0.82 | CCNA2 (0.32) | CCNA2CDK2GRM1 | |
| SCHEMBL24996463 | 0.80 | LMNA (0.34) | CCNA2CDK2 | |
| SCHEMBL24251776 | 0.76 | IAPP (0.45) | CCNA2CDK2GRM1ALDH1A1KDM4E | |
| SCHEMBL30276222 | 0.73 | KMT2A (0.35) | CCNA2CDK2GRM1ALDH1A1HTT | |
| SCHEMBL24496547 | 0.73 | KMT2A (0.35) | CCNA2CDK2GRM1ALDH1A1HTT | |
| SCHEMBL24496570 | 0.73 | CYP1A2 (0.31) | — | |
| SCHEMBL24251664 | 0.70 | CYP1A2 (0.37) | CCNA2CDK2GRM1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| EP-4382511-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | Abbisko Therapeutics Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-117440945-A | Pyrimidine or pyridine derivative, preparation method thereof and application thereof in pharmacy | 上海和誉生物医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-115836064-A | Triazine derivative with EGFR (epidermal growth factor receptor) inhibitory activity and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2023011505-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | 上海和誉生物医药科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2022033455-A1 | TRIAZINE DERIVATIVE HAVING EGFR INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | WEE1, WEE2, EGFR | CCNA2 1749/4885CDK2 131/4885S1PR4 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.